Rise Advisors, LLC Celldex Therapeutics, Inc. Transaction History
Rise Advisors, LLC
- $206 Million
- Q4 2024
A detailed history of Rise Advisors, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Rise Advisors, LLC holds 83 shares of CLDX stock, worth $1,684. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83
Previous 83
-0.0%
Holding current value
$1,684
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
199Shares Held
60.4MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$103 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$95.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$78.8 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$76.2 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$72.2 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $949M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...